FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib

被引：0
|
作者：
Lixia Gao
Xuli Wang
Yaoliang Tang
Shuang Huang
Chien-An Andy Hu
Yong Teng
机构：
[1] Augusta University,Department of Oral Biology, Dental College of Georgia
[2] University of Utah,Department of Radiology and Imaging Sciences, School of Medicine
[3] University of Utah,Experimental Therapeutics Program, Huntsman Cancer Institute
[4] Augusta University,Vascular Biology Center, Department of Medicine, Medical College of Georgia
[5] University of Florida College of Medicine,Department of Anatomy and Cell Biology
[6] University of New Mexico School of Medicine,Department of Biochemistry and Molecular Biology
[7] Augusta University,Department of Biochemistry and Molecular Biology, Medical College of Georgia
来源：
Journal of Experimental & Clinical Cancer Research | / 36卷
关键词：
FGF19; FGFR4; Hepatocellular carcinoma; Drug resistance; Sorafenib; Synergistic effect;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Development of a Potent and Specific FGFR4 Inhibitor for the Treatment of Hepatocellular Carcinoma
    Miranda, Renata Rezende
    Fu, Ying
    Chen, Xiaojuan
    Perino, John
    Cao, Ping
    Carpten, John
    Chen, Yongheng
    Zhang, Chao
    JOURNAL OF MEDICINAL CHEMISTRY, 2020, 63 (20) : 11484 - 11497
  • [22] FGF19 sustains the high proliferative ability of keratinocytes in psoriasis through the regulation of Wnt/GSK-3β/β-catenin signalling via FGFR4
    Yu, Xiaoyun
    Yan, Ning
    Li, Zihai
    Hua, Yunhui
    Chen, Wei
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2019, 46 (08) : 761 - 769
  • [23] Aberrant FGFR4 signaling worsens nonalcoholic steatohepatitis in FGF21KO mice
    Yu, Youxi
    Shi, Xiaoju
    Zheng, Qianqian
    Wang, Xingtong
    Liu, Xingkai
    Tan, Min
    Lv, Guoyue
    Zhang, Ping
    Martin, Robert C.
    Li, Yan
    INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, 2021, 17 (10): : 2576 - 2589
  • [24] Mechanisms of resistance to sorafenib and the corresponding strategies in hepatocellular carcinoma
    Zhai, Bo
    Sun, Xue-Ying
    WORLD JOURNAL OF HEPATOLOGY, 2013, 5 (07) : 345 - 352
  • [25] Sorafenib Resistance in Hepatocellular Carcinoma: The Relevance of Genetic Heterogeneity
    Cabral, Loraine Kay D.
    Tiribelli, Claudio
    Sukowati, Caecilia H. C.
    CANCERS, 2020, 12 (06) : 1 - 19
  • [26] Targeted inhibition of the FGF19-FGFR4 pathway in hepatocellular carcinoma; translational safety considerations
    Mellor, Howard R.
    LIVER INTERNATIONAL, 2014, 34 (06) : E1 - E9
  • [27] Multiple Roles of Autophagy in the Sorafenib Resistance of Hepatocellular Carcinoma
    Sun, Ting
    Liu, Hongchun
    Ming, Liang
    CELLULAR PHYSIOLOGY AND BIOCHEMISTRY, 2017, 44 (02) : 716 - 727
  • [28] Mechanisms of resistance to sorafenib and the corresponding strategies in hepatocellular carcinoma
    Bo Zhai
    Xue-Ying Sun
    World Journal of Hepatology, 2013, (07) : 345 - 352
  • [29] FGFR4 and EZH2 inhibitors synergistically induce hepatocellular carcinoma apoptosis via repressing YAP signaling
    Yiqi Yang
    Yibo Zhang
    Jieqiong Cao
    Zijian Su
    Fu Li
    Peiguang Zhang
    Bihui Zhang
    Rongzhan Liu
    Linhao Zhang
    Junye Xie
    Jingsheng Li
    Jinting Zhang
    Xiaojia Chen
    An Hong
    Journal of Experimental & Clinical Cancer Research, 42
  • [30] CCL22 signaling contributes to sorafenib resistance in hepatitis B virus-associated hepatocellular carcinoma
    Gao, Yanan
    Fan, Xing
    Li, Nan
    Du, Chengzhi
    Yang, Bin
    Qin, Wenhao
    Fu, Jing
    Markowitz, Geoffrey J.
    Wang, Hongyang
    Ma, Jianli
    Cheng, Shuqun
    Yang, Pengyuan
    PHARMACOLOGICAL RESEARCH, 2020, 157
12345